Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

AUTOR(ES)

Hassan, N

RESUMO

Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days. Passive stretch responses were measured before administration and for four hours afterwards. DS103-282 was more effective than baclofen, and both drugs were more effective than placebo. Analysis of the recordings confirmed that DS103-282 had a specific effect upon stretch reflexes independent of its effect on resting muscle tone. Its action appeared at 30 to 45 minutes after ingestion, with maximum activity at 60-90 minutes. Unwanted effects of DS103-282 were drowsiness and (in one case) potentiation of antihypertensive therapy.

Documentos Relacionados

• Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]
• Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis.
• Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.
• Intrathecal baclofen for treatment of spasticity.
• Postgonococcal urethritis: a double-blind study of doxycycline vs placebo.